Delving into the Latest Updates on HSK41959 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

HSK41959

Target

PRMT5

Action

inhibitors

Mechanism

PRMT5 inhibitors(Protein arginine methyltransferase 5 inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Methylthioadenosine phosphorylase deletion cancer

Inactive Indication-

Originator Organization

Shanghai Haisishengnuo Pharmaceutical Technology Co., Ltd

Active Organization

Shanghai Haisishengnuo Pharmaceutical Technology Co., Ltd

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价HSK41959 片在MTAP缺失的晚期实体瘤受试者中的安全性和耐受性；确定 II 期临床试验推荐剂量（RP2D）。次要目的：评价HSK41959 片在MTAP缺失的晚期实体瘤受试者中的药代动力学特征；初步评价HSK41959 片在MTAP缺失的晚期实体瘤受试者中的疗效。探索性目的：评价MTAP 缺失的晚期实体瘤受试者血液中SDMA浓度的变化。

[Translation]

Primary purpose: Evaluate the safety and tolerability of HSK41959 tablets in subjects with advanced solid tumors with MTAP deletion; determine the recommended dose (RP2D) for Phase II clinical trials. Secondary purpose: Evaluate the pharmacokinetic characteristics of HSK41959 tablets in subjects with advanced solid tumors with MTAP deletion; Preliminary evaluation of the efficacy of HSK41959 tablets in subjects with advanced solid tumors with MTAP deletion. Exploratory purpose: Evaluate the changes in SDMA concentration in the blood of subjects with advanced solid tumors with MTAP deletion.

Start Date11 Apr 2025

Sponsor / Collaborator

Shanghai Haisishengnuo Pharmaceutical Technology Co., Ltd

100 Clinical Results associated with HSK41959

Login to view more data

100 Translational Medicine associated with HSK41959

Login to view more data

100 Patents (Medical) associated with HSK41959

Login to view more data

100 Deals associated with HSK41959

Login to view more data